Aclaris Therapeutics (ACRS) Insider Trading & Ownership $2.05 -0.13 (-5.96%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Aclaris Therapeutics (NASDAQ:ACRS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.40%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$2.98 MNumber OfInsiders Selling(Last 12 Months)0 Get ACRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Aclaris Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ACRS Insider Buying and Selling by Quarter Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Aclaris Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/30/2024Braden Michael LeonardMajor ShareholderBuy173,730$1.30$225,849.00 7/22/2024Braden Michael LeonardMajor ShareholderBuy17,716$1.33$23,562.28 7/18/2024Braden Michael LeonardMajor ShareholderBuy130,317$1.30$169,412.10 7/5/2024Braden Michael LeonardMajor ShareholderBuy123,017$1.15$141,469.55 7/3/2024Braden Michael LeonardMajor ShareholderBuy143,288$1.16$166,214.08 7/1/2024Braden Michael LeonardMajor ShareholderBuy107,434$1.14$122,474.76 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/27/2024Braden Michael LeonardMajor ShareholderBuy235,000$1.15$270,250.00 6/17/2024Braden Michael LeonardMajor ShareholderBuy150,000$1.13$169,500.00 6/13/2024Braden Michael LeonardMajor ShareholderBuy528,621$1.15$607,914.15 6/11/2024Braden Michael LeonardMajor ShareholderBuy1,000,000$1.08$1,080,000.00 (Data available from 1/1/2013 forward) ACRS Insider Trading Activity - Frequently Asked Questions Who is on Aclaris Therapeutics's Insider Roster? The list of insiders at Aclaris Therapeutics includes Andrew N Schiff, Braden Michael Leonard, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kevin Balthaser, and Neal Walker. Learn more on insiders at ACRS. What percentage of Aclaris Therapeutics stock is owned by insiders? 6.40% of Aclaris Therapeutics stock is owned by insiders. Learn more on ACRS's insider holdings. Which Aclaris Therapeutics insiders have been buying company stock? The following insiders have purchased ACRS shares in the last 24 months: Braden Michael Leonard ($2,976,645.92), Douglas J Manion ($50,310.00), and James Loerop ($99,994.00). How much insider buying is happening at Aclaris Therapeutics? Insiders have purchased a total of 2,630,328 ACRS shares in the last 24 months for a total of $3,126,949.92 bought. Which Aclaris Therapeutics insiders have been selling company stock? The following insiders have sold ACRS shares in the last 24 months: James Loerop ($59,268.63), Joseph Monahan ($398,556.00), Kevin Balthaser ($12,290.00), and Neal Walker ($739,980.00). How much insider selling is happening at Aclaris Therapeutics? Insiders have sold a total of 97,067 Aclaris Therapeutics shares in the last 24 months for a total of $1,210,094.63 sold. Aclaris Therapeutics Key ExecutivesDr. Neal S. Walker D.O. (Age 54)M.D., Co-Founder, President, Chairman & Interim CEO Compensation: $73.5kMr. Kevin Balthaser (Age 36)Chief Financial Officer Compensation: $581.52kDr. Joseph Monahan Ph.D. (Age 67)Chief Scientific Officer Compensation: $492.43kMr. James Loerop (Age 59)Chief Business Officer Compensation: $570kMr. Matthew Rothman J.D.General Counsel & Corporate SecretaryDr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryMr. Steve TuckerSenior Vice President of Project LeadershipMr. Ajay Aggarwal M.B.A.M.D., Senior Vice President of Clinical Development More Insider Trading Tools from MarketBeat Related Companies Humacyte Insider Buying CorMedix Insider Buying Korro Bio Insider Buying Neoleukin Therapeutics Insider Buying Acelyrin Insider Buying Corvus Pharmaceuticals Insider Buying Nuvation Bio Insider Buying Q32 Bio Insider Buying Mereo BioPharma Group Insider Buying Monte Rosa Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:ACRS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
